BELLUS Health, a Phase 2 biotech developing an oral small molecule therapy for chronic cough, filed on Tuesday with the SEC to raise up to $60 million in an initial public offering in the US. The company is currently listed in Toronto under the symbol BLU.
The Quebec, Canada-based company plans to raise $60 million. Based on the last close on the TSX (C$9.34; $7.03 as-converted), this implies a roughly 8.5 million share offering, and a post-IPO fully diluted market value of $394 million.
The Quebec, Canada-based company traces its roots to 1993, and plans to list on the Nasdaq under the symbol BLU. Jefferies, Cowen and Guggenheim Securities are the joint bookrunners on the deal. It is expected to price later this week.
Investment Disclosure: Renaissance IPO ETF (symbol: IPO) Renaissance International ETF (symbol: IPOS)